CLOs on the Move

Aeon Biopharma

www.aeonbiopharma.com

 
Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.aeonbiopharma.com
  • 4040 Macarthur Boulevard Suite 310
    Newport Beach, CA USA 92660
  • Phone: 949.354.6401

Executives

Name Title Contact Details
Alex Wilson
 General Counsel Profile
Scott Akamine
 General Counsel Profile
Scott Akamine
 General Counsel and Secretary Profile

Similar Companies

Hart Design Group

Hart Design Group is a Cumberland, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Red White and Bloom

The Company is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major US markets, including Michigan, Illinois, Massachusetts and California with respect to cannabis, and the US and internationally for hemp-based CBD products.

Healthstore Holdings

Our proprietary and vertically integrated technology solutions empower clients to improve patient outcomes and enhance medication adherence through improved access (virtual care and MTM), owned pharmacy infrastructure and physician network, information...

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.

Learn to Live CBT

Learn to Live offers online therapy programs for Stress, Depression and Social Anxiety based on the proven principles of Cognitive Behavioral Therapy (CBT).